Table 3.
Distribution of chemotherapy administration, efficacy and toxicity in the three different patient’s groups
| Characteristic | Adjunctive chemotherapy group (n = 13) | Primary FOLFIRI group (n = 10) | Primary FOLFOX group (n = 8) |
| Chemotherapy cycles given per patient | |||
| Range | 3-6 | 2-12 | 3-12 |
| Median | 6 | 7 | 8 |
| Response to chemotherapy (%) | |||
| CR/PR | - | 2 (20.0) | 2 (25.0) |
| SD | - | 5 (50.0) | 5 (62.5) |
| PD | - | 2 (20.0) | 1 (12.5) |
| Not applicable | 13 | 1 (10.0) | 0 |
| Discontinuation of chemotherapy | |||
| Due to death | 1 | 1 | 0 |
| Due to toxicity | 1 | 0 | 1 |
CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; FOLFIRI: 5-fluorouracil, leucovorin and irinotecan combination; FOLFOX: 5-fluorouracil, leucovorin and oxaliplatin combination; RFA: Radiofrequency ablation.